Jonothon Gross, Jonothon Gross, M.D.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Other Securities
    Ineligible company:
    Pfizer
    Date added:
    09/26/2023
    Date updated:
    01/29/2026
  • Attribution:
    Self
    Type of financial relationship:
    Other Securities
    Ineligible company:
    Novartis
    Date added:
    09/26/2023
    Date updated:
    01/29/2026
  • Attribution:
    Self
    Type of financial relationship:
    Other Securities
    Ineligible company:
    Merck
    Date added:
    09/26/2023
    Date updated:
    01/29/2026
  • Attribution:
    Self
    Type of financial relationship:
    Other Securities
    Ineligible company:
    Johnson & Johnson
    Date added:
    09/26/2023
    Date updated:
    01/29/2026
  • Attribution:
    Self
    Type of financial relationship:
    Other Securities
    Ineligible company:
    Gilead
    Date added:
    09/26/2023
    Date updated:
    01/29/2026
  • Attribution:
    Self
    Type of financial relationship:
    Other Securities
    Ineligible company:
    Eli Lilly
    Date added:
    02/19/2025
    Date updated:
    01/29/2026
  • Attribution:
    Self
    Type of financial relationship:
    Other Securities
    Ineligible company:
    Novo Nordisk
    Date added:
    02/19/2025
    Date updated:
    01/29/2026
Return to 0850_ABSMC_PGR:A Person Centered Approach to Financial Capacity and Exploitation Vulnerability _RSS_03/02/2026